Re-engineering Cellular Medicine

A cell engineering company harnessing the power of genetics to develop cellular therapies

Double helix DNA
iPSC cells differentiating into human neural, muscle, blood, bone cells

Technology Overview

Induced Pluripotent stem cells (iPSCs) are derived from somatic cells by temporary expression of four transcription factors, also referred to as the Yamanaka Factors. iPSCs share all the characteristics of embryonic stem cells. As illustrated, iPSCs have the ability to differentiate into all human cell types.

Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.

iPSCs drawn from patient, repaired, differentiated, and returned to same patient

Universal Hypoimmunogenic Approach

The hypoimmunogenic, or universal hypoimmunogenic approach, is a universal cell designed to be
used for all patients.

Personalized Autologous Approach

The autologous approach is a
patient-specific therapy.

iPSCs drawn from donor, repaired, differentiated, used for all patients

Join our team

Join us as we re-engineer cellular medicine.